Carvedilol

Overview

Carvedilol is a non-selective beta blocker with alpha-1 blocking activity primarily used for the treatment of mild to moderate congestive heart failure and hypertension. It helps to decrease heart rate and dilate blood vessels to improve blood flow.

API suppliers (25)

Suppliers of Carvedilol evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.

• MATRIX PHARMACORP PRIVATE LTDIndia2 active DMF
• TAPI NL BVNetherlands2 active DMF
• ZAKLADY FARMACEUTYCZNE POLPHARMA SA1 active DMF
• RAKS PHARMA PVT LTDIndia1 active DMF
• MOEHS IBERICA SLSpain1 active DMF GMP on record
• Sun Pharmaceutical Industries LimitedIndia1 active DMF GMP on record
• Lupin LimitedIndia1 active DMF GMP on record
• Taro Pharmaceutical Industries Ltd.Israel1 active DMF GMP on record
• Cadila Pharmaceuticals LimitedIndia1 active DMF GMP on record
• Zhejiang Huahai Pharmaceutical Co., Ltd.China1 active DMF GMP on record
• Ipca Laboratories LimitedIndia1 active DMF GMP on record
• Macleods Pharmaceuticals Ltd.India1 active DMF GMP on record
• ALIVUS LIFE SCIENCES LTDIndia1 active DMF GMP on record
• Zydus Lifesciences LimitedIndia1 active DMF GMP on record
• APITORIA PHARMA PRIVATE LTDIndia1 active DMF GMP on record
• Cipla USA, Inc.USA
• ZACH SYSTEM SPA GMP on record
• WANBURY LTDIndia
• ROCHE DIAGNOSTICS GMBH GMP on record
• Cipla LimitedIndiaCEP GMP on record
• ORCHID CHEMICALS AND PHARMACEUTICALS LTD
• ZENTIVA AS GMP on record
• DR REDDYS LABORATORIES LTD GMP on record
• Egis Pharmaceuticals PLCHungaryCEP GMP on record
• CAMBREX CHARLES CITY INCUnited States

EU CEP holders (12)

Companies holding a valid EU Certificate of Suitability (CEP) for Carvedilol, from the EDQM certification database. A CEP holder is a documented EU-market source of the substance — not necessarily the manufacturer — and these are not yet profiled in our directory.

Patent & exclusivity (US)

Per the FDA Orange Book (56 approved US products), the latest listed US patent on Carvedilol expires 11 Mar 2026. Generic API sourcing typically opens up once these lapse.

Therapeutic areas